by David Cassak
Barely heard of five years ago, medical device incubators have been springing up in those geographic pockets known for medical...
The notion of incubators is catching on quickly in medical devices, thanks in part to a difficult financing climate and, in part, to the desire of some executives to find a new career path, focused on mentoring companies and leveraging skill sets across a number of projects at once. Designed primarily to get early stage product ideas to proof of principle quickly, incubators are overcoming skepticism about their proper role and beginning to make their mark on the device industry. In this two-part series, we look at several different incubator models
by David Cassak
Barely heard of five years ago, medical device incubators have been springing up in those geographic pockets known for medical...
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.